PaySign Inc

PaySign, Inc. engages in the provision of prepaid card programs and processing services for corporate, consumer and government applications. It specializes in corporate incentive products, payroll cards, general purpose re-loadable cards, and travel cards. It markets its prepaid solutions through its PaySign brand. The company was founded by Mark R. Newcomer and Daniel H. Spencer on August 24, 1995 and is headquartered in Henderson, NV.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PaySign Inc (PAYS) reports robust Q4 earnings and growth outlook

PaySign Inc (PAYS) delivered a strong financial performance in Q4 2022, with revenue growth, profitability, and operational achievements.
The company's focus on expanding its plasma business and patient affordability programs has been key drivers of growth and market differentiation.
Looking ahead, PaySign aims for continued growth in 2023, supported by revenue projections and strategic initiatives to drive profitability and market expansion.

PaySign Inc reports strong revenue growth, eyes plasma business expansion

PaySign Inc's Q1 2023 performance reflects solid revenue growth and operational progress, despite facing margin and profitability challenges.
The company's strengths lie in the growth potential of its Plasma and Patient affordability businesses, along with strategic industry partnerships.
While challenges persist in maintaining margins and addressing profitability, PaySign Inc has opportunities to drive growth through new center openings and market expansion.
Overall, PaySign Inc's financial position remains stable with a focus on executing its growth strategies and enhancing profitability.

PaySign Inc reports strong Q2 revenue growth and expansion plans

PaySign Inc (PAYS) delivered robust revenue growth in Q2 2023, driven by strong performance in key segments and a focus on expanding its market presence.
While facing challenges such as a net loss and increased SG&A expenses, the company remains optimistic about its growth prospects and profitability trajectory.
By capitalizing on opportunities in plasma compensation and patient affordability segments, PaySign Inc aims to sustain its growth momentum and enhance shareholder value.

PaySign Inc (PAYS) reports strong Q3 earnings and growth prospects

PaySign Inc (PAYS) delivered robust financial results in Q3 2023, showcasing growth across key business segments.
Despite challenges such as new center openings and contract delays, the company remains focused on meeting its financial targets.
With a strong balance sheet, diversified revenue streams, and strategic outlook, PaySign Inc (PAYS) is well-positioned for future success.

PaySign Inc reports stellar Q4 results, eyes growth opportunities

PaySign Inc delivered strong financial results in Q4 2023, with notable revenue growth and net income increase, driven by the success of its plasma and patient affordability segments.
The company's strategic focus on revenue diversification, technology development, and market expansion positions it well for future growth and competitive advantage.
While facing challenges in sustaining growth rates and navigating competitive landscapes, PaySign has opportunities to capitalize on market demand, innovation, and ethical business practices to drive continued success.
Overall, PaySign's performance highlights operational excellence, strategic foresight, and a commitment to delivering value to stakeholders, setting a positive trajectory for 2024 and beyond.

PaySign Inc reports robust Q1 earnings, eyes growth opportunities

PaySign Inc delivered impressive financial results in Q1 2024, driven by strong revenue growth and improved profitability.
While facing challenges in sustaining growth and market competition, the company remains optimistic about future prospects.
Strategic expansion in key business segments and a positive market reception position PaySign Inc for continued success.

PaySign Inc (PAYS) reports stellar Q2 results and raises 2024 guidance

PaySign Inc demonstrated robust financial performance in Q2 2024, driven by strong revenue growth, improved profitability, and expansion of key client relationships. While facing some challenges in specific business segments, the company's strategic initiatives and raised guidance indicate a positive trajectory for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PaySign, Inc. (PAYS) Q4 2023 Earnings Call Transcript

For the Full Year Full-year 2023 total revenues of $47.3 million, up 24% from full-year 2022 Full-year 2023 net income of $6.5 million, or diluted earnings per share of $0.12, versus net income of $1.0 million, or diluted earnings per share of $0.02 for full-year 2022 Full-year 2023 Adjusted EBITDA of $6.7 million, up 21% from $5.5 million a year ago, while diluted Adjusted EBITDA per share was $0.12 versus $0.10 for full-year 20221 Total plasma center count increased by 20 during 2023, exiting the year with 464 centers, contributing to a 21% increase in plasma revenue versus the same period last year Launched 24 net new patient affordability programs during 2023, exiting the year with 43 active programs, leading to a 35% increase in pharma revenue and a 172% increase in pharma patient affordability revenue over the same period last year Exited the year with $17.0 million of unrestricted cash and zero debt while repurchasing 394,558 shares of common stock for $1.1 million Full-year 2023 gross dollar load volume was up 7% over 2022 Full-year 2023 gross spend volume was up 10% over 2022 For the Fourth Quarter Fourth quarter 2023 total revenues of $13.7 million, up 29% from fourth quarter 2022 Fourth quarter 2023 net income of $5.6 million, or diluted earnings per share of $0.10 Fourth quarter 2023 Adjusted EBITDA of $2.5 million, up 43% from $1.7 million a year ago, while diluted Adjusted EBITDA per share was $0.05 versus $0.03 for the fourth quarter 20221 Added two net new plasma donation centers during the fourth quarter of 2023, exiting the quarter with 464 centers, helping contribute to a 19% increase in plasma revenue over the same period last year Launched nine net new patient affordability programs during the fourth quarter of 2023, exiting the quarter with 43 active programs, leading to a 132% increase in pharma revenue and a 247% increase in pharma patient affordability revenue over the same period last year Fourth quarter 2023 gross dollar load volume up 9% versus the year-ago period Fourth quarter 2023 gross spend volume was up 8% versus the year-ago period Fourth quarter 2023 average revenue per plasma center per month of $8,297, up 14%, versus $7,293 for the fourth quarter of 2022 1 Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net income to Adjusted EBITDA at the end of the press release. HENDERSON, NV / ACCESSWIRE / March 26, 2024 / Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial results for the fourth quarter and full-year 2023.

Paysign, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results

ATHENS, Greece--(BUSINESS WIRE)-- #IPPC2024--Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17.

Paysign, Inc. to Sponsor the 2024 International Plasma Protein Congress April 16-17

HENDERSON, Nev.--(BUSINESS WIRE)-- #executiveteam--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced a key executive recruitment that supports their foundation as an end-to-end payment processor. Sandy Ortins, AAP, APRP, NCP, was brought on as the company's vice president of electronic funds transfer (EFT) services, an essential addition to the team. Prior to joinin.

Paysign, Inc. Reinforces Payment Processing Acumen With New Executive Hire

BOSTON--(BUSINESS WIRE)-- #patientaffordability--Payysign, Inc. to sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29.

Paysign, Inc. to Sponsor the 2024 Gene Therapy for Rare Disorders Conference March 26-29

PHILADELPHIA--(BUSINESS WIRE)--Paysign Inc. to Sponsor the 2024 ACCESS USA Conference March 19-21.

Paysign Inc. to Sponsor the 2024 ACCESS USA Conference March 19-21

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, will discuss fourth quarter and full year 2023 earnings at 5:00 p.m. EDT on Tuesday, March 26, 2024. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay Dial-in: 877.660.6853 or +1.201.612.7415 Conference.

Paysign to Host Fourth Quarter and Full Year 2023 Earnings Call

Akoustis Technologies

Compass Diversified Holdings

Edgewise Therapeutics

Occidental Petroleum

PBF Energy

RXO Inc

While investors shouldn't get too focused on any one signal, a great source of confidence stems from insider favorite stocks. As the old adage goes, it's difficult to tell what insider selling means.

Insider Favorites: 7 Stocks with Bullish Buying Signals

Ardelyx

Ballard Power Systems

Nordic American Tankers

Overseas Shipholding Group

Pitney Bowes

PHX Minerals

In the ever-evolving investment landscape, penny stocks to buy emerge as the thrill-seekers' darlings. Known for their high-risk, high-reward nature, these stocks attract investors with their low share prices and the promise of substantial gains.

7 Penny Stocks You'll Regret Not Buying Soon: November 2023

PaySign, Inc. (NASDAQ:PAYS ) Q3 2023 Earnings Conference Call November 7, 2023 5:00 PM ET Company Participants Mark Newcomer - Chief Executive Officer Jeff Baker - Chief Financial Officer Conference Call Participants Gary Prestopino - Barrington Research Operator Good afternoon. My name is Kevin, and I'll be your conference operator today.

PaySign, Inc. (PAYS) Q3 2023 Earnings Call Transcript

Third quarter total revenues of $12.4 million, an increase of 17% compared to third quarter 2022 Third quarter net income of $1.1 million and diluted income per share of $0.02 Third quarter Adjusted EBITDA of $2.3 million, an increase of 22% compared to third quarter 2022, and diluted Adjusted EBITDA per share of $0.04, unchanged from third quarter 20221 Added 19 net new plasma donation centers during the third quarter, exiting the quarter with 462 centers, leading to a 13% increase in plasma revenue over the same period last year Launched three new patient affordability programs during the third quarter, exiting the quarter with 34 active programs, leading to a 142% increase in pharma patient affordability revenue over the same period last year Third quarter average revenue per plasma center per month of $8,102 up 7.8% compared to third quarter 2022 Exited quarter with $9.9 million of unrestricted cash and zero debt while repurchasing 75,000 shares of common stock for $150 thousand, bringing year-to-date share repurchases to 394,558 for $1.1 million 1Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net income to Adjusted EBITDA at the end of the press release. HENDERSON, NV / ACCESSWIRE / November 7, 2023 / Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial results for the third quarter 2023.

Paysign, Inc. Reports Third Quarter 2023 Financial Results

Terran Orbital Corp

Ammo

In times of market turmoil, penny stocks often get overlooked by investors seeking refuge in more stable blue chip stocks. However, for the enterprising investor, penny stocks can offer intriguing avenues to potentially turn a small investment into a much larger sum.

3 Penny Stocks to Buy to Turn $1 into $100: October 2023

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing, will discuss third quarter 2023 earnings at 5:00 p.m. EST on Tuesday, November 7, 2023. Participant details are as follows: U.S. dial-in: 877.407.2988 International dial-in: +1.201.389.0923 Webcast: Click Here Replay: Dial-in: 877.660.6853 or +1.201.612.7415 Conference ID: 13742205.

Paysign to Host Third Quarter 2023 Earnings Call

Blade Air Mobility

Flux Power Holdings

In this market, many penny stocks continue to remain beaten down. That said, while I don't expect each and every speculative penny stock to surge higher like they did in 2021, select penny stocks still offer tremendous upside.

3 Penny Stocks to Invest In for Big-Time, Long-Term Gains

Advantage Solutions

Butler National Corporation

Comstock Holding Companies

Flexible Solutions

Smith Micro Software

The performance of penny stocks continues to be mixed relative to more widely-followed stocks, but if you've looking for the best penny stocks to buy now, this works to your advantage. As has been the case in recent months, there are plenty of names in “penny stock territory” ($5 per share or less) trading at low valuations, with catalysts in play that over the long-term stand to help bridge the gap between trading price and underlying value.

The 7 Best Penny Stocks to Buy Now

PaySign, Inc. (NASDAQ:PAYS ) Q2 2023 Results Conference Call August 9, 2023 5:00 PM ET Company Participants Mark Newcomer - CEO Jeff Baker - CFO Matt Turner - President, Patient Affordability Conference Call Participants Gary Prestopino - Barrington Research Jon Hickman - Ladenburg Operator Good afternoon. My name is Kevin, and I'll be your conference operator today.

PaySign, Inc. (PAYS) Q2 2023 Earnings Call Transcript

Second quarter total revenues of $11.0 million, an increase of 28% compared to second quarter 2022 Second quarter net loss of ($0.1) million and diluted loss per share of ($0.00) Second quarter Adjusted EBITDA of $1.1 million, an increase of 23% compared to second quarter 2022, and diluted Adjusted EBITDA per share of $0.02, unchanged from second quarter 2022 (Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP metrics used by management to gauge the operating performance of the business - see reconciliation of net loss to Adjusted EBITDA at the end of the press release) Added four net new plasma donation centers during the second quarter, exiting the quarter with 443 centers Launched five new patient affordability programs during the second quarter, exiting the quarter with 31 active programs, leading to a 133% increase in pharma patient affordability revenue Second quarter gross dollar load volume up 7.9% and gross spend volume up 11.1% compared to second quarter 2022 Repurchased 119,558 shares of common stock for $312 thousand, bringing year-to-date share repurchases to 319,558 HENDERSON, NV / ACCESSWIRE / August 8, 2023 / Paysign, Inc. (NASDAQ:PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial results for the second quarter 2023 ended June 30, 2023. "We delivered strong revenue growth this quarter, a year-over-year increase of 28%, supported by the continued positive momentum in our plasma, patient affordability, and other areas of our business," said CEO Mark Newcomer.

Paysign, Inc. Reports Second Quarter 2023 Financial Results

B2Gold

Globalstar

GEE Group

Jerash holdings (US) Inc

Procaps Group SA

Bottom-fishers, take note: there are scores of penny stock opportunities out there. While major stocks have been on a year so far this year, penny stocks (or stocks trading for $5 per share or less) have delivered a more mixed performance.

7 Penny Stocks Nearing Super Attractive Entry Points

Abacus Life Inc

Beneficient

Euronet Worldwide

Reliance Global Group

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.

Top 5 Financial Stocks You'll Regret Missing This Quarter - Beneficient (NASDAQ:BENF), Abacus Life (NASDAQ:ABL)

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Participate in the August 2023 Sidoti Micro-Cap Virtual Investor Conference.

Paysign, Inc. to Participate in the August 2023 Sidoti Micro-Cap Virtual Investor Conference

Burke & Herbert Financial Services Corp

Netcapital Inc

Top Kingwin Ltd

Top 5 Financial Stocks That May Rocket Higher In Q3

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Oppenheimer 26th Annual Technology, Internet and Communications Conference.

Paysign, Inc. to Present at the Oppenheimer 26th Annual Technology, Internet and Communications Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host Second Quarter 2023 Earnings Call.

Paysign to Host Second Quarter 2023 Earnings Call

The company has steadily amassed a dominant position in plasma centers and is set for further steady growth. Despite the loss of its prepaid pharma business, it's the pharma segment, still tiny, where additional growth seems now likely. The company has had some recent wins and is in talks with a number of big pharma companies.

PaySign Is Finally Getting Promising Traction In Its Pharma Business

HENDERSON, Nev.--(BUSINESS WIRE)--Paysign Successfully Completes Certification and Establishes Connection with Mastercard.

News for PaySign Inc Stock (PAYS)